查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1945275

2026年全球血液学和肿瘤学检测市场报告

Hemato Oncology Testing Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，血液学和肿瘤学检测市场发展迅速，预计将从2025年的39.3亿美元成长到2026年的45亿美元，复合年增长率达14.4%。过去几年的增长可归因于多种因素，包括血液系统癌症发病率的上升、医院诊断检查室的扩张、人们对癌症早期检测意识提升、临床研究活动的增加以及先进检测试剂的广泛应用。

预计未来几年血液肿瘤检测市场将快速成长，到2030年市场规模将达到77.6亿美元，复合年增长率（CAGR）为14.6%。预测期内的成长要素包括精准肿瘤诊断技术的日益普及、基因组检测基础设施投资的增加、人工智慧驱动的诊断平台的扩展、伴随诊断需求的成长以及检测技术的持续创新。预测期内的关键趋势包括分子诊断检测技术的日益普及、次世代定序在肿瘤学领域的应用日益广泛、个性化癌症诊断需求的增长、自动化检测平台的扩展以及数据分析在血液肿瘤学领域日益增强的整合。

血液系统恶性肿瘤发生率的不断上升预计将推动血液肿瘤检测市场的成长。血液系统恶性肿瘤是指起源于血液、骨髓和淋巴系统的癌症，包括白血病、淋巴瘤和骨髓瘤等疾病。早期诊断对这些疾病至关重要，而血液肿瘤检测在实现早期诊断方面发挥关键作用。例如，根据英国癌症研究中心（Cancer Research UK ）估计，截至2025年9月，英国白血病的发生率约为每年每10万人17.9例，预计与2020年至2024年相比将呈下降趋势。 2024年至2026年，英国白血病的发生率预计仍约为每年每10万人17.9例，预计到2038年至2040年将下降3%，至约每10万人17.4例。因此，血液肿瘤盛行率的上升是推动血液肿瘤检测市场发展的关键因素。

血液学和肿瘤学检测市场的主要企业正在引入诸如次世代定序(NGS) 等新技术，以提高基因分析的准确性和速度，实现对骨髓恶性肿瘤的全面分析，并支持针对个别患者需求的个人化治疗策略。 NGS 是一种高通量DNA测序技术，能够快速、经济高效地分析整个基因组或特定 DNA 区域。例如，2024 年 10 月，专注于癌症诊断和基因组检测的美国公司 NeoGenomics Inc. 推出了 AML Express，这是一款旨在快速检测与急性骨髓性白血病(AML) 相关的突变的次世代定序工具。这款先进的诊断平台可提供高精度且快速的检测结果，帮助肿瘤科医师及时做出有针对性的治疗决策。 AML Express 旨在透过提供 AML 特定基因谱的精准突变资讯来改善患者的治疗效果。

目录

第一章执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 全球血液学和肿瘤学检测市场：吸引力评分和分析
  • 成长潜力分析、竞争评估、策略契合度评估、风险状况评估

第三章 市场供应链分析

  • 供应链与生态系概述
  • 主要原料、资源和供应商清单
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章 全球市场趋势与策略

  • 关键技术和未来趋势
    • 生物技术、基因组学和精准医学
    • 人工智慧与自主智能
    • 数位化、云端运算、巨量资料、网路安全
    • 工业4.0和智慧製造
    • 物联网 (IoT)、智慧基础设施和互联生态系统
  • 主要趋势
    • 分子诊断检测的应用日益广泛
    • 肿瘤学中次世代定序的广泛应用
    • 对个人化癌症诊断的需求日益增长
    • 扩展自动化测试平台
    • 加强血液学和肿瘤学中数据分析的整合

第五章 终端用户产业市场分析

  • 医院
  • 诊断检查室
  • 学术研究机构
  • 肿瘤诊所
  • CRO（受託研究机构）

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及新冠疫情对市场的影响

第七章 全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球血液学和肿瘤学检测市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 全球血液学及肿瘤学检测市场规模、对比及成长率分析
  • 全球血液学和肿瘤学检测市场表现：规模和成长，2020-2025年
  • 全球血液学和肿瘤学检测市场预测：规模和成长，2025-2030年，2035年预测

第八章 全球潜在市场规模（TAM）

第九章 市场细分

  • 按产品/服务
  • 检测试剂盒、试剂和服务
  • 癌症类型
  • 白血病、淋巴瘤、多发性骨髓瘤
  • 透过技术
  • 聚合酵素链锁反应（PCR）、免疫组织化学（IHC）、次世代定序（NGS）
  • 最终用户
  • 医院、学术研究机构
  • 按类型细分：检测试剂盒和试剂
  • PCR试剂盒、次世代定序（NGS）试剂盒、流式细胞技术试剂、抗体
  • 按类型细分：服务
  • 测试服务、数据分析服务

第十章 区域与国家分析

  • 全球血液学及肿瘤学检测市场：区域表现及预测，2020-2025年、2025-2030年预测、2035年预测
  • 全球血液学和肿瘤学检测市场：按国家/地区、绩效和预测划分，2020-2025年、2025-2030年预测、2035年预测

第十一章 亚太市场

第十二章：中国市场

第十三章 印度市场

第十四章 日本市场

第十五章：澳洲市场

第十六章 印尼市场

第十七章 韩国市场

第十八章 台湾市场

第十九章 东南亚市场

第二十章：西欧市场

第21章英国市场

第22章 德国市场

第23章：法国市场

第24章：义大利市场

第25章：西班牙市场

第26章 东欧市场

第27章：俄罗斯市场

第28章 北美市场

第29章：美国市场

第30章：加拿大市场

第31章 南美洲市场

第32章：巴西市场

第33章 中东市场

第34章：非洲市场

第35章 市场监理与投资环境

第三十六章：竞争格局与公司概况

  • 血液学和肿瘤学检测市场：竞争格局和市场份额，2024 年
  • 血液学和肿瘤学检测市场：公司估值矩阵
  • 血液学和肿瘤学检测市场：公司概况
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Illumina Inc.
    • Invivoscribe Inc.

第37章：其他领先和创新企业

  • Qiagen NV, Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings

第38章 全球市场竞争基准分析与仪錶板

第39章 重大併购

第四十章：高潜力市场国家、细分市场与策略

  • 2030年血液学和肿瘤学检测市场：提供新机会的国家
  • 2030年血液学和肿瘤学检测市场：充满新机会的细分市场
  • 2030年血液学和肿瘤学检测市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第41章附录

简介目录
Product Code: ME3MHOTN01_G26Q1

Hemato-oncology testing involves diagnostic procedures designed to identify symptoms of blood disorders and blood cancers. These tests play a crucial role in diagnosing conditions such as anemia, infections, hemophilia, blood-clotting disorders, and leukemia.

The primary products and services associated with hemato-oncology testing include assay kits, reagents, and testing services. Assay kits and reagents encompass instruments and chemicals utilized together to analyze specific substances. The testing procedures cover various cancer types, including leukemia, lymphoma, multiple myeloma, and others. The technologies employed for these tests include polymerase chain reaction (PCR), immunohistochemistry (IHC), next-generation sequencing (NGS), and other advanced techniques. The end-users of hemato-oncology testing include hospitals, academic and research institutes, and other healthcare entities.

Tariffs are influencing the hemato oncology testing market by increasing costs of imported reagents, sequencing instruments, laboratory automation systems, and analytical software components. Diagnostic laboratories and hospitals in North America and Europe are most affected due to dependence on imported high-end testing equipment, while Asia-Pacific faces cost pressures on reagent manufacturing and export. These tariffs are raising operational expenses and test pricing. However, they are also promoting domestic reagent production, regional equipment manufacturing, and localized development of diagnostic technologies.

The hemato oncology testing market research report is one of a series of new reports from The Business Research Company that provides hemato oncology testing market statistics, including hemato oncology testing industry global market size, regional shares, competitors with a hemato oncology testing market share, detailed hemato oncology testing market segments, market trends and opportunities, and any further data you may need to thrive in the hemato oncology testing industry. This hemato oncology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hemato oncology testing market size has grown rapidly in recent years. It will grow from $3.93 billion in 2025 to $4.5 billion in 2026 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to rising incidence of blood cancers, expansion of hospital diagnostic laboratories, increasing awareness of early cancer detection, growth in clinical research activities, availability of advanced testing reagents.

The hemato oncology testing market size is expected to see rapid growth in the next few years. It will grow to $7.76 billion in 2030 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to increasing adoption of precision oncology diagnostics, rising investments in genomic testing infrastructure, expansion of AI-driven diagnostic platforms, growing demand for companion diagnostics, continuous innovation in assay technologies. Major trends in the forecast period include increasing adoption of molecular diagnostic testing, rising use of next-generation sequencing in oncology, growing demand for personalized cancer diagnostics, expansion of automated laboratory testing platforms, enhanced integration of data analytics in hemato-oncology.

The anticipated rise in the incidence of hematologic cancer is set to be a driving force behind the growth of the hemato-oncology testing market. Hematologic cancer encompasses a group of cancers originating in the blood, affecting the blood, bone marrow, and lymphatic system, including conditions such as leukemia, lymphoma, and myeloma. Early diagnosis is crucial for these diseases, and hemato-oncology testing plays a pivotal role in achieving this. For instance, in September 2025, according to Cancer Research UK, a UK-based charity, From 2024 to 2026, the incidence rate of leukemia in the UK is estimated at approximately 17.9 cases per 100,000 people per year, and it is projected to decrease by 3% to around 17.4 per 100,000 by 2038 to 2040. Hence, the increasing prevalence of hematologic cancers is a significant driver propelling the hemato-oncology testing market forward.

Key companies in the hemato-oncology testing market are implementing new innovations such as next-generation sequencing (NGS) to enhance the accuracy and speed of genetic analysis, enable comprehensive profiling of hematologic malignancies, and support personalized treatment strategies tailored to the needs of individual patients. NGS is a high-throughput DNA sequencing technology that facilitates rapid and cost-effective analysis of entire genomes or specific DNA regions. For example, in October 2024, NeoGenomics Inc., a U.S.-based company specializing in cancer diagnostics and genomic testing, launched AML Express, a next-generation sequencing tool designed for the swift detection of mutations related to Acute Myeloid Leukemia (AML). This advanced diagnostic platform provides high accuracy and quick turnaround times, assisting oncologists in making timely and targeted treatment decisions. AML Express aims to enhance patient outcomes by delivering precise mutation insights tailored to the specific genetic profiles associated with AML.

In January 2023, Merck & Co. Inc., a leading US-based pharmaceutical company, acquired Imago BioSciences, Inc., a biotechnology company focusing on diagnostic and therapeutic products for hemato-oncology testing and related blood disorders. This acquisition aligns with Merck's commitment to fortify its presence in the hematology field by investing in innovative solutions and strengthening its pipeline.

Major companies operating in the hemato oncology testing market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina Inc., Invivoscribe Inc., Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings, Agilent Technologies, Danaher Corporation, Grifols SA, Diaorin SpA, HTG Molecular Diagnostics Inc., Admera Health

North America was the largest region in the hemato oncology testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global hemato oncology testing market report during the forecast period. The regions covered in the hemato oncology testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hemato oncology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hemato oncology testing market consists of revenues earned by entities by providing sampling and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemato-oncology testing market also includes the sales of consumables and instruments which are used to provide hemato-oncology testing services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hemato Oncology Testing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses hemato oncology testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hemato oncology testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hemato oncology testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Product And Services: Assay Kits And Reagents; Services
  • 2) By Cancer Type: Leukemia; Lymphoma; Multiple Myeloma
  • 3) By Technology: Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); Next-Generation Sequencing (NGS)
  • 4) By End User: Hospitals; Academic And Research Institutes
  • Subsegments:
  • 1) By Assay Kits And Reagents: PCR Kits; Next-Generation Sequencing (NGS) Kits; Flow Cytometry Reagents; Antibodies
  • 2) By Services: Testing Services; Data Analysis Services
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Thermo Fisher Scientific Inc.; Illumina Inc.; Invivoscribe Inc.; Qiagen N.V.; Bio-Rad Laboratories Inc.; Archerdx Inc.; ARUP Laboratories Inc.; Asuragen Inc.; Adaptive Biotechnologies Corp.; Cepheid Inc.; EntroGen Inc.; CORE Diagnostics Inc.; Genoptix Inc.; GenPath Diagnostics; NeoGenomics Laboratories Inc.; Siemens AG; Sysmex Corporation; Laboratory Corporation of America Holdings; Agilent Technologies; Danaher Corporation; Grifols SA; Diaorin SpA; HTG Molecular Diagnostics Inc.; Admera Health
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Hemato Oncology Testing Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Hemato Oncology Testing Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Hemato Oncology Testing Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Hemato Oncology Testing Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics And Precision Medicine
    • 4.1.2 Artificial Intelligence And Autonomous Intelligence
    • 4.1.3 Digitalization, Cloud, Big Data And Cybersecurity
    • 4.1.4 Industry 4.0 And Intelligent Manufacturing
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure And Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Molecular Diagnostic Testing
    • 4.2.2 Rising Use Of Next-Generation Sequencing In Oncology
    • 4.2.3 Growing Demand For Personalized Cancer Diagnostics
    • 4.2.4 Expansion Of Automated Laboratory Testing Platforms
    • 4.2.5 Enhanced Integration Of Data Analytics In Hemato-Oncology

5. Hemato Oncology Testing Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Diagnostic Laboratories
  • 5.3 Academic And Research Institutes
  • 5.4 Oncology Specialty Clinics
  • 5.5 Contract Research Organizations

6. Hemato Oncology Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Hemato Oncology Testing Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Hemato Oncology Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Hemato Oncology Testing Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Hemato Oncology Testing Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Hemato Oncology Testing Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Hemato Oncology Testing Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Hemato Oncology Testing Market Segmentation

  • 9.1. Global Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Assay Kits And Reagents, Services
  • 9.2. Global Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Leukemia, Lymphoma, Multiple Myeloma
  • 9.3. Global Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS)
  • 9.4. Global Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals, Academic And Research Institutes
  • 9.5. Global Hemato Oncology Testing Market, Sub-Segmentation Of Assay Kits And Reagents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • PCR Kits, Next-Generation Sequencing (NGS) Kits, Flow Cytometry Reagents, Antibodies
  • 9.6. Global Hemato Oncology Testing Market, Sub-Segmentation Of Services, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Testing Services, Data Analysis Services

10. Hemato Oncology Testing Market Regional And Country Analysis

  • 10.1. Global Hemato Oncology Testing Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Hemato Oncology Testing Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Hemato Oncology Testing Market

  • 11.1. Asia-Pacific Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Hemato Oncology Testing Market

  • 12.1. China Hemato Oncology Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Hemato Oncology Testing Market

  • 13.1. India Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Hemato Oncology Testing Market

  • 14.1. Japan Hemato Oncology Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Hemato Oncology Testing Market

  • 15.1. Australia Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Hemato Oncology Testing Market

  • 16.1. Indonesia Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Hemato Oncology Testing Market

  • 17.1. South Korea Hemato Oncology Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Hemato Oncology Testing Market

  • 18.1. Taiwan Hemato Oncology Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Hemato Oncology Testing Market

  • 19.1. South East Asia Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Hemato Oncology Testing Market

  • 20.1. Western Europe Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Hemato Oncology Testing Market

  • 21.1. UK Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Hemato Oncology Testing Market

  • 22.1. Germany Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Hemato Oncology Testing Market

  • 23.1. France Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Hemato Oncology Testing Market

  • 24.1. Italy Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Hemato Oncology Testing Market

  • 25.1. Spain Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Hemato Oncology Testing Market

  • 26.1. Eastern Europe Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Hemato Oncology Testing Market

  • 27.1. Russia Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Hemato Oncology Testing Market

  • 28.1. North America Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Hemato Oncology Testing Market

  • 29.1. USA Hemato Oncology Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Hemato Oncology Testing Market

  • 30.1. Canada Hemato Oncology Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Hemato Oncology Testing Market

  • 31.1. South America Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Hemato Oncology Testing Market

  • 32.1. Brazil Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Hemato Oncology Testing Market

  • 33.1. Middle East Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Hemato Oncology Testing Market

  • 34.1. Africa Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Hemato Oncology Testing Market Regulatory and Investment Landscape

36. Hemato Oncology Testing Market Competitive Landscape And Company Profiles

  • 36.1. Hemato Oncology Testing Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Hemato Oncology Testing Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Hemato Oncology Testing Market Company Profiles
    • 36.3.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Invivoscribe Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Hemato Oncology Testing Market Other Major And Innovative Companies

  • Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings

38. Global Hemato Oncology Testing Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Hemato Oncology Testing Market

40. Hemato Oncology Testing Market High Potential Countries, Segments and Strategies

  • 40.1 Hemato Oncology Testing Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Hemato Oncology Testing Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Hemato Oncology Testing Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer